Idioma:

Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain

Riebenfeld, Daniela ; Spirk, David ; Mathis, Alexandra ; Villiger, Lukas ; Gerber, Philipp A ; Gasser, Urs Erwin ; Lehmann, Roger

Swiss medical weekly, 2015-03, Vol.145 (910), p.w14114-w14114 [Periódico revisado por pares]

Switzerland: SMW supporting association (Trägerverein Swiss Medical Weekly SMW)

Texto completo disponível

Citações Citado por

Enviar para

Título:
Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain
Autor: Riebenfeld, Daniela ; Spirk, David ; Mathis, Alexandra ; Villiger, Lukas ; Gerber, Philipp A ; Gasser, Urs Erwin ; Lehmann, Roger
Assuntos: Aged ; Blood Glucose - drug effects ; ClikSTAR ; Diabetes Mellitus, Type 2 - drug therapy ; Fasting ; Female ; Glycated Hemoglobin A - drug effects ; Glycated Hemoglobin A - metabolism ; Humans ; Hypoglycemic Agents - administration & dosage ; insulin glargine ; Insulin Glargine - administration & dosage ; Male ; Middle Aged ; Patient empowerment ; Patient Preference ; primary care ; Prospective Studies ; Type-2 diabetes mellitus ; weight ; Weight Gain - drug effects
É parte de: Swiss medical weekly, 2015-03, Vol.145 (910), p.w14114-w14114
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
Descrição: We aimed to evaluate the efficacy of, and treatment satisfaction with, insulin glargine administered with SoloSTAR® or ClikSTAR® pens in patients with type 2 diabetes mellitus managed by primary care physicians in Switzerland. A total of 327 patients with inadequately controlled type 2 diabetes were enrolled by 72 physicians in this prospective observational study, which aimed to evaluate the efficacy of a 6-month course of insulin glargine therapy measured as development of glycaemic control (glycosylated haemoglobin [HbA1c] and fasting plasma glucose [FPG]) and weight change. We also assessed preference for reusable or disposable pens, and treatment satisfaction. After 6 months, the mean daily dose of insulin glargine was 27.7±14.3 U, and dose titration was completed in 228 (72.4%) patients. Mean HbA1c decreased from 8.9%±1.6% (n=327) to 7.3%±1.0% (n=315) (p<0.0001), and 138 (43.8%) patients achieved an HbA1c≤7.0%. Mean FPG decreased from 10.9±4.5 to 7.3±1.8 mmol/l (p<0.0001). Mean body weight did not change (85.4±17.2 kg vs 85.0±16.5 kg; p=0.11). Patients' preference was in favour of the disposable SoloStar® pen (80%), as compared with the reusable ClickStar® pen (20%). Overall, 92.6% of physicians and 96.3% of patients were satisfied or very satisfied with the insulin glargine therapy. In patients with type 2 diabetes insulin glargine administered by SoloSTAR® or ClikSTAR® pens, education on insulin injection and on self-management of diabetes was associated with clinically meaningful improvements in HbA1c and FPG without a mean collective weight gain. The vast majority of both patients and primary care physicians were satisfied with the treatment intensification.
Editor: Switzerland: SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain

Riebenfeld, Daniela ; Spirk, David ; Mathis, Alexandra ; Villiger, Lukas ; Gerber, Philipp A ; Gasser, Urs Erwin ; Lehmann, Roger

Switzerland: SMW supporting association (Trägerverein Swiss Medical Weekly SMW)

Buscando em bases de dados remotas. Favor aguardar.